Examining the impact of inducible ischemia on myocardial fibrosis and exercise capacity in hypertrophic cardiomyopathy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
29 09 2020
29 09 2020
Historique:
received:
07
04
2020
accepted:
11
08
2020
entrez:
30
9
2020
pubmed:
1
10
2020
medline:
13
1
2021
Statut:
epublish
Résumé
Myocardial ischemia in hypertrophic cardiomyopathy (HCM) is associated with poor outcomes. Vasodilator stress cardiac magnetic resonance (CMR) can detect and quantitate inducible ischemia in HCM patients. We hypothesized that myocardial ischemia assessed by CMR is associated with myocardial fibrosis and reduced exercise capacity in HCM. In 105 consecutive HCM patients, we performed quantitative assessment of left ventricular volume and mass, wall thickness, segmental wall thickening percent, segmental late Gadolinium enhancement (LGE), and extracellular volume fraction (ECV). Time-signal intensity curves of first pass perfusion sequences were generated for each segment at stress and rest. A myocardial perfusion reserve index (MPRI) (stress/rest slope) was calculated. Patients who underwent an echocardiographic (n = 73) and cardiopulmonary exercise test (n = 37) within 30 days were included. The mean age was 53.2 ± 15.4 years; 60% were male, and 82 patients had asymmetric hypertrophy. Segments with end diastolic thickness ≥ 1.2 cm had a higher burden of LGE (4.1% vs 0.5% per segment), reduced MPRI (2.6 ± 1.5 vs 3.1 ± 1.8) and reduced thickening percent (48.9 ± 41.7% vs. 105.3 ± 59.5%), (P < 0.0001 for all comparisons). Patients with ischemia (any segment with MPRI < 2) were more likely to have dynamic left ventricular outflow tract (LVOT) obstruction (63.3% vs 36.7%, P = 0.01), to be smokers (17% vs 6.9%, P = 0.04), and had a higher ECV (30% vs 28%, P = 0.04). The total LGE burden was similar between the two groups (P = 0.47). Increasing ischemia burden (number of segments with MPRI < 2) was associated with worsened ventilatory efficiency (VE/VCO2) (P < 0.001) but not peak oxygen consumption or anerobic threshold (P > 0.2). In a patient-level multivariable logistic regression model, only LVOT obstruction remained a significant predictor of ischemia burden (P = 0.03). Myocardial ischemia by CMR is associated with myocardial segmental dysfunction and interstitial fibrosis, as assessed by ECV, in HCM patients, even in segments free of LGE. Conversely, quantitative ischemia burden was not associated with replacement fibrosis as assessed by total LGE burden. Patients with ischemia had greater prevalence of dynamic LVOT obstruction; and in a subset of patients with cardiopulmonary exercise testing, ischemia burden was associated with worsened ventilatory efficiency.
Identifiants
pubmed: 32994462
doi: 10.1038/s41598-020-71394-z
pii: 10.1038/s41598-020-71394-z
pmc: PMC7524770
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
15977Subventions
Organisme : NIH HHS
ID : 1R01HL137763-01
Pays : United States
Références
Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249–1254 (2015).
doi: 10.1016/j.jacc.2015.01.019
Geske, J. B., Ommen, S. R. & Gersh, B. J. Hypertrophic cardiomyopathy: clinical update. JACC Heart Failure https://doi.org/10.1016/j.jchf.2018.02.010 (2018).
doi: 10.1016/j.jchf.2018.02.010
pubmed: 29655825
Cecchi, F. et al. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N. Engl. J. Med. 349, 1027–1035 (2003).
doi: 10.1056/NEJMoa025050
Olivotto, I. et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 47, 1043–1048 (2006).
doi: 10.1016/j.jacc.2005.10.050
Maron, B. J., Wolfson, J. K., Epstein, S. E. & Roberts, W. C. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 8, 545–557 (1986).
doi: 10.1016/S0735-1097(86)80181-4
Schwartzkopff, B., Mundhenke, M. & Strauer, B. E. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J. Am. Coll. Cardiol. 31, 1089–1096 (1998).
doi: 10.1016/S0735-1097(98)00036-9
Raphael, C. E. et al. Mechanisms of myocardial ischemia in hypertrophic cardiomyopathy: insights from wave intensity analysis and magnetic resonance. J. Am. Coll. Cardiol. 68, 1651–1660 (2016).
doi: 10.1016/j.jacc.2016.07.751
Gersh, B. J. et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of cardiology foundation/American heart association task force on practice guidelines. Circulation 124 (2011).
Zamorano, J. L. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733–2779 (2014).
doi: 10.1093/eurheartj/eht569
Choudhury, L. et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 40, 2156–2164 (2002).
doi: 10.1016/S0735-1097(02)02602-5
Swoboda, P. P. et al. Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from athlete’s heart. J. Am. Coll. Cardiol. 67, 2189–2190 (2016).
doi: 10.1016/j.jacc.2016.02.054
Sado, D. M. et al. Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart 98, 1436–1441 (2012).
doi: 10.1136/heartjnl-2012-302346
Raman, B. et al. Progression of myocardial fibrosis in hypertrophic cardiomyopathy: mechanisms and clinical implications. Eur. Heart J. Cardiovasc. Imaging 20, 157–167 (2019).
doi: 10.1093/ehjci/jey135
Tower-Rader, A., Betancor, J., Lever, H. M. & Desai, M. Y. A comprehensive review of stress testing in hypertrophic cardiomyopathy: assessment of functional capacity, identification of prognostic indicators, and detection of coronary artery disease. J. Am. Soc. Echocardiogr. 30, 829–844 (2017).
doi: 10.1016/j.echo.2017.05.017
Elliott, P. M. et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur. Heart J. 35, 2733–2779 (2014).
doi: 10.1093/eurheartj/ehu199
Maragiannis, D. et al. Left ventricular function in patients with hypertrophic cardiomyopathy and its relation to myocardial fibrosis and exercise tolerance. Int. J. Cardiovasc. Imaging 34, 121–129 (2018).
doi: 10.1007/s10554-017-1214-z
Kotecha, T. et al. Automated pixel-wise quantitative myocardial perfusion mapping by cmr to detect obstructive coronary artery disease and coronary microvascular dysfunction. JACC Cardiovasc. Imaging https://doi.org/10.1016/j.jcmg.2018.12.022 (2019).
doi: 10.1016/j.jcmg.2018.12.022
pubmed: 31202744
Dass, S. et al. Myocardial tissue characterization using magnetic resonance noncontrast T1 mapping in hypertrophic and dilated cardiomyopathy. Circ. Cardiovasc. Imaging 5, 726–733 (2012).
doi: 10.1161/CIRCIMAGING.112.976738
Maron, M. S. et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295–303 (2003).
doi: 10.1056/NEJMoa021332
O’Mahony, C. et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM Risk-SCD). Eur. Heart J. 35, 2010–2020 (2014).
doi: 10.1093/eurheartj/eht439
Wigle, E. D., Sole, M. J. & Williams, W. C. Pathologic fibrosis and matrix connective tissue in the subaortic myocardium of patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 17, 1343–1351 (1991).
doi: 10.1016/S0735-1097(10)80145-7
Tyan, C. C. et al. Stress hypoperfusion and tissue injury in hypertrophic cardiomyopathy: spatial characterization using high-resolution 3-tesla magnetic resonance imaging. Circ. Cardiovasc. Imaging 6, 229–238 (2013).
doi: 10.1161/CIRCIMAGING.112.000170
Villa, A. D. M. et al. Microvascular ischemia in hypertrophic cardiomyopathy: new insights from high-resolution combined quantification of perfusion and late gadolinium enhancement. J. Cardiovasc. Magn. Reson. 18, 4 (2016).
doi: 10.1186/s12968-016-0223-8
Magrì, D. et al. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. Heart 102, 602–609 (2016).
doi: 10.1136/heartjnl-2015-308453
Larghat, A. M. et al. Reproducibility of first-pass cardiovascular magnetic resonance myocardial perfusion. J. Magn. Reson. Imaging 37, 865–874 (2013).
doi: 10.1002/jmri.23889
Klocke, F. J. et al. Limits of detection of regional differences in vasodilated flow in viable myocardium by first-pass magnetic resonance perfusion imaging. Circulation 104, 2412–2416 (2001).
doi: 10.1161/hc4501.099306
Petersen, S. E. et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 115, 2418–2425 (2007).
doi: 10.1161/CIRCULATIONAHA.106.657023